Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.

AIDS-Related Opportunistic Infections / drug therapy Africa South of the Sahara / epidemiology Animals Anti-Retroviral Agents / adverse effects Biomarkers Coinfection / epidemiology Endemic Diseases Epidemics Guinea Pigs HIV Humans Mycobacterium tuberculosis / physiology Prevalence Transcriptome Tuberculosis / epidemiology

Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
03 2019
Historique:
received: 14 01 2018
revised: 18 07 2018
accepted: 19 07 2018
pubmed: 18 12 2018
medline: 6 5 2020
entrez: 18 12 2018
Statut: ppublish

Résumé

Tuberculosis claims more human lives than any other infectious disease. This alarming epidemic has fuelled the development of novel antimicrobials and diagnostics. However, public health interventions that interrupt transmission have been slow to emerge, particularly in HIV-endemic settings. Transmission of tuberculosis is complex, involving various environmental, bacteriological, and host factors, among which concomitant HIV infection is important. Preventing person-to-person spread is central to halting the epidemic and, consequently, tuberculosis transmission is now being studied with renewed interest. In this Series paper, we review recent advances in the understanding of tuberculosis transmission, from the view of source-case infectiousness, inherent susceptibility of exposed individuals, appending tools for predicting risk of disease progression, the biophysical nature of the contagion, and the environments in which transmission occurs and is sustained in populations. We focus specifically on how HIV infection affects these features with a view to describing novel transmission blocking strategies in HIV-endemic settings.

Identifiants

DOI: 10.1016/S1473-3099(18)30477-8 PMID: 30554995 PMC: PMC6401310
pubmed: 30554995
pii: S1473-3099(18)30477-8
doi: 10.1016/S1473-3099(18)30477-8
pmc: PMC6401310
mid: NIHMS1521855
pii:
doi:

Substances chimiques

Anti-Retroviral Agents 0
Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e65-e76

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI052073
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI130058
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI104411
Pays : United States
Organisme : NIAID NIH HHS
ID : DP2 AI131082
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI106420
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124349
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Ann Intern Med. 1999 Oct 19;131(8):557-63
pubmed: 10523215
Postgrad Med J. 2000 May;76(895):259-68
pubmed: 10775277
AIDS. 2000 Mar 31;14(5):525-35
pubmed: 10780715
Int J Tuberc Lung Dis. 2000 May;4(5):455-62
pubmed: 10815740
Lancet. 2000 Sep 23;356(9235):1066-71
pubmed: 11009142
Int J Tuberc Lung Dis. 2000 Dec;4(12):1104-10
pubmed: 11144451
Clin Infect Dis. 2001 Dec 1;33(11):1922-30
pubmed: 11692305
Lancet. 2001 Nov 17;358(9294):1687-93
pubmed: 11728545
Int J Tuberc Lung Dis. 2002 Oct;6(10):843-50
pubmed: 12365569
South Med J. 2003 Feb;96(2):155-7
pubmed: 12630640
Clin Infect Dis. 2003 May 15;36(10):1305-12
pubmed: 12746777
Am Rev Tuberc. 1957 Mar;75(3):420-31
pubmed: 13403171
Am Rev Respir Dis. 1962 Apr;85:511-25
pubmed: 14492300
J Infect Dis. 2003 Oct 15;188(8):1156-63
pubmed: 14551886
JAMA. 1992 Sep 9;268(10):1280-6
pubmed: 1507374
Thorax. 2005 Feb;60(2):130-5
pubmed: 15681501
Am J Respir Crit Care Med. 2005 Jun 15;171(12):1430-5
pubmed: 15831840
Clin Infect Dis. 2006 Apr 1;42(7):1040-7
pubmed: 16511773
Emerg Infect Dis. 2006 May;12(5):729-35
pubmed: 16704828
Am J Respir Crit Care Med. 2007 Jan 1;175(1):87-93
pubmed: 16973982
Clin Infect Dis. 2007 May 15;44(10):1349-57
pubmed: 17443474
Lancet. 2007 Oct 27;370(9597):1500-7
pubmed: 17964351
Pathol Res Pract. 2008;204(3):155-61
pubmed: 18096327
Tubercle. 1948 Nov;29(11):245-51
pubmed: 18101320
BMC Public Health. 2008 Jan 14;8:15
pubmed: 18194573
Emerg Infect Dis. 2007 Oct;13(10):1491-3
pubmed: 18257992
Int J Tuberc Lung Dis. 2008 Aug;12(8):942-8
pubmed: 18647455
J Infect Dis. 2008 Oct 1;198(7):1037-43
pubmed: 18702608
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13280-5
pubmed: 18728189
PLoS Med. 2008 Sep 30;5(9):e188
pubmed: 18798687
PLoS One. 2008;3(12):e4094
pubmed: 19116662
Immunology. 2009 Sep;128(1):123-33
pubmed: 19191912
PLoS One. 2009;4(5):e5420
pubmed: 19412539
Lancet. 2009 Sep 12;374(9693):921-33
pubmed: 19709731
Am J Respir Crit Care Med. 2010 Jan 15;181(2):174-80
pubmed: 19875686
J Exp Med. 2009 Nov 23;206(12):2583-91
pubmed: 19901083
J Infect Dis. 2010 Jan 1;201(1):15-9
pubmed: 19938975
AIDS. 2010 Jan 28;24(3):417-26
pubmed: 20042847
Am J Public Health. 2011 Mar;101(3):524-30
pubmed: 20516372
Clin Infect Dis. 2010 Oct 1;51(7):830-2
pubmed: 20735239
Clin Infect Dis. 2010 Oct 1;51(7):823-9
pubmed: 20735240
PLoS Med. 2010 Dec 21;7(12):e1000381
pubmed: 21203587
PLoS One. 2010 Dec 29;5(12):e15735
pubmed: 21209951
Am J Trop Med Hyg. 2011 Jan;84(1):30-7
pubmed: 21212197
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):230-8
pubmed: 21239993
Infect Immun. 2011 Apr;79(4):1407-17
pubmed: 21245275
Clin Microbiol Rev. 2011 Apr;24(2):351-76
pubmed: 21482729
Curr HIV Res. 2011 Sep;9(6):383-92
pubmed: 21999773
PLoS One. 2011;6(10):e25098
pubmed: 22016763
Respir Med. 2012 Feb;106(2):197-204
pubmed: 22100538
Clin Infect Dis. 2012 Apr;54(7):968-71
pubmed: 22291100
PLoS Pathog. 2012 Feb;8(2):e1002464
pubmed: 22363214
J Infect Dis. 2012 May 15;205 Suppl 2:S265-73
pubmed: 22448015
PLoS One. 2012;7(3):e34156
pubmed: 22479548
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9557-62
pubmed: 22645356
Am J Respir Crit Care Med. 2012 Sep 1;186(5):450-7
pubmed: 22798319
Int J Tuberc Lung Dis. 2012 Nov;16(11):1510-6
pubmed: 22990075
Eur Respir J. 2013 Nov;42(5):1291-301
pubmed: 23100496
Am J Respir Crit Care Med. 2013 Mar 1;187(5):543-51
pubmed: 23262515
Am J Respir Crit Care Med. 2013 May 1;187(9):1007-15
pubmed: 23306539
Int J Tuberc Lung Dis. 2013 Mar;17(3):361-7
pubmed: 23407224
Am J Epidemiol. 2013 Mar 15;177(6):556-61
pubmed: 23423215
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
Am J Trop Med Hyg. 2013 Jul;89(1):169-73
pubmed: 23629934
Clin Infect Dis. 2013 Oct;57(7):963-70
pubmed: 23800941
PLoS One. 2013 Jun 27;8(6):e67516
pubmed: 23826313
PLoS One. 2013 Aug 05;8(8):e70630
pubmed: 23940611
PLoS One. 2013 Sep 17;8(9):e75466
pubmed: 24069418
PLoS Med. 2013 Oct;10(10):e1001538
pubmed: 24167453
Pathog Dis. 2014 Mar;70(2):110-8
pubmed: 24214523
Clin Microbiol Infect. 2014 Jan;20(1):10-6
pubmed: 24267942
Clin Infect Dis. 2014 Mar;58(6):765-74
pubmed: 24368620
N Engl J Med. 2014 Jan 23;370(4):301-10
pubmed: 24450889
J Infect Dis. 2014 Aug 15;210(4):597-603
pubmed: 24610874
Euro Surveill. 2014 Mar 06;19(9):null
pubmed: 24626210
Clin Infect Dis. 2014 Jun;58(12):1676-83
pubmed: 24647020
Immunology. 2014 Apr;141(4):506-13
pubmed: 24754048
N Engl J Med. 2014 May 01;370(18):1712-1723
pubmed: 24785206
Int J Tuberc Lung Dis. 2014 Jul;18(7):758-9
pubmed: 24902546
BMC Infect Dis. 2014 Jun 27;14:352
pubmed: 24970328
PLoS One. 2014 Jul 02;9(7):e100984
pubmed: 24988000
J Infect Dis. 2015 Jan 1;211(1):53-61
pubmed: 25053739
J Infect Dis. 2015 Jan 15;211(2):317-21
pubmed: 25143445
J Infect Dis. 2015 Apr 1;211(7):1154-63
pubmed: 25336729
J Infect Dis. 2015 May 1;211(9):1367-72
pubmed: 25387581
PLoS One. 2014 Nov 13;9(11):e111209
pubmed: 25393281
Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91
pubmed: 25562578
Emerg Infect Dis. 2015 Mar;21(3):452-5
pubmed: 25642998
J Theor Biol. 2015 May 7;372:100-6
pubmed: 25702940
Int J Tuberc Lung Dis. 2015 Apr;19(4):375-80
pubmed: 25859990
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
BMC Infect Dis. 2015 Aug 21;15:361
pubmed: 26293293
J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):104-8
pubmed: 26322671
Am J Epidemiol. 2016 Jan 15;183(2):156-66
pubmed: 26646292
J Infect Dis. 2016 Apr 1;213(7):1173-9
pubmed: 26690346
PLoS One. 2016 Jan 25;11(1):e0146658
pubmed: 26807816
Nat Genet. 2016 Mar;48(3):318-22
pubmed: 26829749
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
Lancet Respir Med. 2016 Mar;4(3):213-24
pubmed: 26907218
Lancet. 2016 Jun 4;387(10035):2312-2322
pubmed: 27017310
MBio. 2016 Apr 05;7(2):e00342-16
pubmed: 27048801
Am J Respir Crit Care Med. 2016 Nov 1;194(9):1152-1163
pubmed: 27181053
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1532-1540
pubmed: 27387272
Lancet. 2016 Sep 10;388(10049):1089-1102
pubmed: 27427453
J Infect Dis. 2016 Oct 15;214(8):1260-7
pubmed: 27485354
Eur Respir J. 2016 Dec;48(6):1751-1763
pubmed: 27836953
Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S15
pubmed: 28043518
Lancet Respir Med. 2017 Apr;5(4):269-281
pubmed: 28109869
S Afr Med J. 2016 Dec 21;107(1):4-5
pubmed: 28112082
Thorax. 2017 Jun;72(6):559-575
pubmed: 28115682
Emerg Infect Dis. 2017 Mar;23(3):496-499
pubmed: 28221118
Am J Respir Crit Care Med. 2017 Aug 15;196(4):502-511
pubmed: 28463648
PLoS Genet. 2017 Jun 19;13(6):e1006710
pubmed: 28628665
Sci Rep. 2017 Oct 9;7(1):12800
pubmed: 28993696
J Acquir Immune Defic Syndr. 2018 Jan 01;77(1):93-101
pubmed: 29016524
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1091-1092
pubmed: 29037287
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1147-1154
pubmed: 29037295
J Infect Dis. 2017 Nov 3;216(suppl_6):S662-S668
pubmed: 29112744
J Infect Dis. 2017 Nov 3;216(suppl_6):S644-S653
pubmed: 29112745
J Infect Dis. 2017 Nov 3;216(suppl_6):S629-S635
pubmed: 29112747
PLoS Pathog. 2017 Nov 16;13(11):e1006687
pubmed: 29145483
BMC Pulm Med. 2017 Dec 13;17(1):202
pubmed: 29237451
Am J Epidemiol. 2017 Dec 15;186(12):1362-1369
pubmed: 29253139
Epidemiol Infect. 2018 Feb;146(3):345-353
pubmed: 29338805
Gates Open Res. 2017 Nov 7;1:11
pubmed: 29355225
Lancet Child Adolesc Health. 2018 Jan;2(1):46-55
pubmed: 29457055
Lancet Respir Med. 2018 Apr;6(4):244-246
pubmed: 29595504
Lancet Infect Dis. 2018 Aug;18(8):e228-e238
pubmed: 29653698
Am Rev Respir Dis. 1987 Sep;136(3):570-4
pubmed: 3631730
JAMA. 1978 Dec 1;240(23):2544-7
pubmed: 712956
AIDS. 1993 Jul;7(7):981-7
pubmed: 8357557
AIDS. 1996 Oct;10(12):1446-7
pubmed: 8902086
Clin Infect Dis. 1997 Jun;24(6):1060-7
pubmed: 9195058
Lancet. 1997 Nov 1;350(9087):1284-7
pubmed: 9357408

Auteurs

Julian S Peters (JS)

Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa.

Jason R Andrews (JR)

Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, CA, USA.

Mark Hatherill (M)

South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Sabine Hermans (S)

Desmond Tutu HIV Centre, Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Cape Town, South Africa; Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.

Leonardo Martinez (L)

Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, CA, USA.

Erwin Schurr (E)

Research Institute of the McGill University Health Centre, Montréal, QC, Canada.

Yuri van der Heijden (Y)

Vanderbilt Tuberculosis Center and Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.

Robin Wood (R)

Desmond Tutu HIV Centre, Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Roxana Rustomjee (R)

Tuberculosis Clinical Research Branch, Therapeutic Research Program, Division of AIDS National Institute of Allergy and Infectious Diseases, National Institutes of Health, North Bethesda, MD, USA.

Bavesh D Kana (BD)

Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa; South African Medical Research Council HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa. Electronic address: bavesh.kana@nhls.ac.za.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Infections opportunistes liées au SIDA › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Eucaryotes › Animaux › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Infection › Co-infection › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Maladies endémiques › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Cochons d'Inde › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Transcriptome › Advances in the understanding of Mycobacterium...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Advances in the understanding of Mycobacterium...